

## DAFTAR PUSTAKA

- Aletaha D, Smolen JS (2009). Outcome Measurement in Rheumatoid Arthritis: Disease Activity. Dalam: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (eds). *Rheumatoid Arthritis Textbook*. Philadelphia: Mosby, Inc, pp: 225-230.
- Bakaa Z, Györgya B, Géherb P, Buzás A, Falusa A, Nagya G (2012). Citrullination under physiological and pathological conditions. *Joint Bone Spine*, 79: 431-436.
- Bright R, Proudman SM, Rosenstein ED, Bartold PM (2015). Is there a link between carbamylation and citrullination in periodontal. *Medical Hypotheses*: 570-576.
- Cope AP (2013). Rheumatoid arhritis. Dalam: Rich RR, Fleisher TA, Shearer WT, Schroeder HW, Frew AJ, Weyand CM (eds). *Clinical Immunology Fourth Edition*: Philadelphia: Elsevier, pp: 621-636.
- Csermely P, Yahara I (2002). Heat shock protein. Molecular Pathomechanism and New Trends in Drug Research: 67-75.
- Da Mota LMH *et al* (2013). Guidelines for the diagnosis of rheumatoid arthritis. *J Rheumatol* 53(2): 141–157.
- Dahlan MS (2014). Statistic untuk kedokteran dan kesehatan. Edisi ke 6. Penerbit: Epidemiologi Indonesia.
- DAS28 (2009). <http://www.das-score.nl/www.das-score.nl/index.html>. Diakses April 2016.
- Del Amo NDV, Bosch RI, Manteca CF, Polo RG, Cortina EL (2006). Anticyclic citrullinated peptide antibody in Rheumatoid Arthritis: Relation with disease aggressiveness. *Clinical and Experimental Rheumatology*: 2006;24:281-6.
- Duckworth AD, Porter DE, Ralston SH (2009). *Orthopaedics, trauma and rheumatology*. Philadelphia: Elsevier.
- Forslind K, Ahlme'n M, Eberhardt K, Hafstro'm I, Svensson B (2003). Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). *Ann Rheum Dis* 2004;63:1090–1095.

- Foulquier C *et al* (2007). Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. *Arthritis & Rheumatism* 56 (11): 3541–3553.
- Fransen J, van Riel PLCM (2005). The disease activity score and the EULAR response criteria. *Clin Exp Rheumatol*: 93-99.
- Gabay C, Nissen MJ, van Laar JM (2015). Rheumatoid arthritis: pathogenesis and clinical features. Dalam: Bijlsma JWJ, Hachulla E (eds). *EULAR Textbook on rheumatic diseases second edition*. London: BMJ, pp: 246-248.
- Hasan H (2010). Korelasi antara rheumatoid factor dan anti cyclic citrullinated peptide dengan aktivitas penyakit pada penderita artritis reumatoид. Padang, Indonesia, Universitas Andalas. Tesis.
- Hochberg MC, Oliver JE, Silman AJ (2009). Risk factors for rheumatoid arthritis: other nongenetic host factors. Dalam: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (eds). *Rheumatoid Arthritis Textbook*. Philadelphia: Mosby, Inc, pp: 35-40.
- Isbagio H (2004). Use of anti-citrullinated peptide (anti-ccp) antibodies in distinguishing patients with systemic lupus erythematosus and rheumatoid arthritis. *J Med Indonesia*: 227-231.
- Kastbom A, Strandberg G, Lindroos A, Skogh T (2004) Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). *Ann Rheum Dis* 63:1085–1089.
- Khosla P, Shankar S, Duggal Lalit (2004). Anti-ccp antibodies in rheumatoid arthritis. *J Rheumatol Assoc* 12: 143-146.
- Kourilovitch M, Maldonado CG, Prado EO (2013). Diagnosis and classification of rheumatoid arthritis. *Journal of Autoimmunity*: 26-30.
- Kroot EJ *et al* (2000). The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. *Arthritis Rheum*. 2000;43(8):1831–5.
- Kuna AT (2011). Mutated citrullinated vimentin antibodies in rheumatoid arthritis. *Clinica Chimica Acta* 413: 66-73.
- Lee DM, Phillips R, Hagan EM, Chibnik LB, Costenbader KH, Schur PH (2007). Quantifying Anti-CCP titer: clinical utility and association with tobacco exposure in patients with rheumatoid arthritis. *Ann Rheum Dis* doi:10.1136/ard.2007.084509.

- Liu D *et al* (2011). Diagnostic value of serum and joint fluid anti-CCP (citrulline-containing peptide) antibody for rheumatoid arthritis and its relationship with other inflammatory indicators. *Scientific Research and Essays* Vol. 6(12), pp: 2465-2469.
- Marsland D, Kapoor S, Coote A, Haslam P (2008). Rheumatoid arthritis. Dalam: Horton-Szar D (ed). *Rheumatology and Orthopaedics* Edisi ke 2. Philadelphia: Elsevier, pp: 59-67.
- Martinez EO, Ramirez DFH, Nunez-Alvarez CA, Cabiedes J (2009). Citrullinated proteins in rheumatoid arthritis. *Reumatol Clin*. 7 (1): 68–71.
- McInnes IB, Schett G (2011). Mechanisms of disease: The pathogenesis of rheumatoid arthritis. *Journal of Medicine*: 2205-2219.
- Merza RR, Tofiq DM, Radhi NN, Khan HAEK (2014). The Association of Anti-CCP and Disease Activity in Rheumatoid Arthritis. *Cukurova Medical Journal* 2014;39(4):743-751.
- Meyer O *et al* (2003). Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. *Ann Rheum Dis* 62:120-126.
- Niewold TB, Harrison MJ, Paget SA (2007). Anti-ccp antibody testing as a diagnostic and prognostic tool in rheumatoid arthritis. *J Medicine* 100: 193-201.
- O'Dell J (2013). Rheumatoid arthritis. Dalam: Firestein G, Budd R, Gabriel SE, McInnes IB, O'Dell J (eds). *Kelley's Textbook of Rheumatology*, 9<sup>th</sup> Edition. Philadelpia: Elsevier, pp: 1755-1756.
- Panayi GS (2005). B cells: A fundamental role in the pathogenesis of rheumatoid arthritis?. *Rheumatology* 44: ii3–ii7.
- Posalski J, Weisman MH (2009). Articular and periarticular manifestations of established rheumatoid arthritis. Dalam: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (eds). *Rheumatoid Arthritis Textbook*. Philadelphia: Mosby, Inc, pp: 49-61.
- Predeteanu D *et al* (2009). Original papers: clinical or basic research anti-cyclic citrullinated peptide antibodies - activity markers in rheumatoid arthritis. *J Med Life*; 2(1): 36–41.
- Raptopoulou A, Sidiropoulos P, Katsouraki M, Boumpa DT (2007). Anti-citrulline antibodies in the diagnosis and prognosis of rheumatoid arthtritis. *Critical Reviews in Clinical Laboratory Sciences*: 339-363.

- Safi MAA, Houssien DA, Scott DL (2012). Disease Activity and Anti-Cyclic Citrullinated Peptide (Anti-CCP) Antibody in Saudi RF-Negative Rheumatoid Arthritis Patients JKAU: Med. Sci., Vol. 19 No. 3, pp: 3-20 (2012 A.D. / 1433 A.H.) DOI: 10.4197/Med. 19-3.1 Sakkas LI, Bogdanos DP, Katsiari C, Platsoucas CD (2014). Anti-citrullinated peptides as autoantigens in rheumatoid arthritis—relevance to treatment. Autoimmunity Reviews 13: 1114-1120.
- Serdaroglu M, ÇakÂrbay H, Defer O, Cengiz S, KulThe S (2008). The association of anti-ccp antibodies with disease activity in rheumatoid arthritis. Rheumatol Int 28: 965-970.
- Shakiba Y *et al* (2014). Anti cyclic citrullinated peptide antibody and rheumatoid factor isotypes in iranian patients with rheumatoid arthritis: evaluation of clinical value and association with disease activity. Iran J Allergy Asthma Immunol 13(3): 147-156.
- Silman AJ, Hochberg MC (2009). Descriptive epidemiology of rheumatoid arthritis. Dalam: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (eds). Rheumatoid Arthritis Textbook. Philadelphia: Mosby, Inc, pp: 15-22.
- Soeroso J (2008). Korelasi antara kadar anti-cyclic citrullinated peptide dengan aktivitas penyakit artritis reumatoid berdasarkan disease activity score-28 dan kadar c-reactive protein. Abstrak Jurnal Penelitian Univ Airlangga: 1.
- Soeroso J (2014). Imunogenetika penyakit reumatis. Dalam: Alwi I, Setiati S, Setiyohadi B, Simadibrata M, Sudoyo AW, Syam AF (eds). Buku Ajar Ilmu Penyakit Dalam Edisi ke 6. Jakarta: Pusat Penerbitan Departemen Ilmu Penyakit Dalam FKUI, pp: 3095-3106.
- Stenberg P, Roth B, Wollheim FA (2009). Peptidylarginine deiminases and the pathogenesis of rheumatoid arthritis: A reflection of the involvement of transglutaminase in coeliac disease. European Journal of Internal Medicine 20: 749-755.
- Suarjana IN (2014). Artritis reumatoid. Dalam: Alwi I, Setiati S, Setiyohadi B, Simadibrata M, Sudoyo AW, Syam AF (eds). Buku Ajar Ilmu Penyakit Dalam Edisi ke 6. Jakarta: Pusat Penerbitan Departemen Ilmu Penyakit Dalam FKUI, pp: 3132-3149.
- Suwito M, Handono K, Kalim H, Suryana BPP, Wahono CS (2010). Correlation between anti-cyclic citrullinated peptide antibodies and the severity of clinical manifestation, laboratory manifestation and radiological joint destruction in rheumatoid arthritis patients. Indonesian Journal of Rheumatology 2(1): 14-17.
- The National Initiative on Pain Control (2006). Pain assessment scales, pp: 2-5

van Gaalen F, Ioan-Facsinay A, Huizinga TWJ, Toes REM (2005). The devil in the details: the emerging role of anticitrulline autoimmunity in rheumatoid arthritis. *J Immunol* 175: 5575-5580.

van Jaarsveld CHM *et al* (1999). The prognostic value of the antiperinuclear factor, anticitrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis. *Clin Exp Rheumatol* 17:689–697.

van Venrooij WJ, van Beers JJBC, Pruijn GJM (2011). Anti-ccp antibodies: the past, the present and the future. *Rheumatology*: 391-398.

Vossenaar ER, Radstake TR, van der Heijden A, van Mansum MA, Dieteren C, de Rooij GJ, et al. Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. *Ann Rheum Dis*.2004;63:373–381.

Visual DAS28 Calculator (2016). <http://www.4s-dawn.com/DAS28/DAS28.html>. Diakses Juli 2016.

Ward MM (2009). Physical Function. Dalam: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (eds). *Rheumatoid Arthritis Textbook*. Philadelphia: Mosby, Inc, pp: 231-236

WHO (2016). <http://www.who.int/chp/topics/rheumatic/en/>. Diakses Mei 2016.

